VIVORYON THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
After market 02:06:30 pm | |||
| 0.82 EUR | -8.38% |
|
0.842 | +2.68% |
| Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
| Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
| Sales 2023 | -3.62K -3.88K | Sales 2024 * | - | Capitalization | 23.33M 25.02M |
|---|---|---|---|---|---|
| Net income 2023 | -28M -30.02M | Net income 2024 * | -18M -19.3M | EV / Sales 2023 | -53,497 x |
| Net cash position 2023 | 18.52M 19.86M | Net cash position 2024 * | 19.55M 20.96M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.25
x | Employees | 15 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics N.V.
More press releases
| 1 day | +24.31% | ||
| 1 week | +112.34% | ||
| Current month | +65.74% | ||
| 1 month | +64.22% | ||
| 3 months | -89.77% | ||
| 6 months | -88.87% | ||
| Current year | -89.00% |
1 week
0.44
1.00
1 month
0.411.00
Current year
0.419.93
1 year
0.4119.56
3 years
0.4123.25
5 years
0.4123.25
10 years
0.4127.73
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.82 | -8.38% | 1 589 391 |
| 24-04-24 | 0.895 | +24.31% | 3,324,608 |
| 24-04-23 | 0.72 | +26.32% | 2,581,230 |
| 24-04-22 | 0.57 | +25.83% | 546,850 |
| 24-04-19 | 0.453 | -3.62% | 99,759 |
Real-time Euronext Amsterdam, April 24, 2024 at 11:38 am EDT
More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-06-11
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.895
EUR
Average target price
41.57
EUR
Spread / Average Target
+4,544.32%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -89.00% | 24.93M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- VVY Stock
